How do you define treatment volumes for patients treated with neoadjuvant chemoimmunotherapy for resectable NSCLC who are no longer surgical candidates or decline surgery?

Topics: Radiation Oncology • Thoracic Malignancies

Do you treat pre-neoadjuvant volumes to full RT dose, or do you modify treatment volumes if there is tumor shrinkage?

Answer from: Radiation Oncologist at Academic Institution

Good question and seeing this more routinely as there is a greater push for a neoadjuvant approach in borderline resectable surgical patients. We don't have patterns of failure data to guide this but I use the same principle/approach I use for LS-SCLC that I'm initiating at C2. Post-chemo/IO primary...

Comments

Radiation Oncologist at West Virginia University
Seems reasonable and I have noticed in my own expe...

Related Questions